Article Sidebar
Views PDF: 0
EVALUATION OF COMBINED SYSTEMIC CORTICOSTEROIDS WITH MYCOPHENOLATE MOFETIL IN VOGT-KOYANAGI-HARADA DISEASE: A CASE SERIES
Main Article Content
Abstract
Vogt-Koyanagi-Harada (VKH) syndrome is an autoimmune disease characterized by bilateral uveitis, which may be accompanied by vitiligo, poliosis, alopecia, meningeal symptoms, and audiovestibular dysfunction. VKH is one of the most common causes of autoimmune uveitis in Asian countries, including Vietnam. The pathogenesis is hypothesized to involve a T-cell-mediated immune response against antigens present in melanocytes of the uveal tract, skin, and central nervous system. Currently, there is no standardized treatment protocol for VKH. Systemic corticosteroids remain the first-line therapy due to their effectiveness in controlling acute inflammation. However, long-term use is associated with significant systemic side effects. Moreover, growing evidence suggests that corticosteroids monotherapy may be insufficient to prevent the disease in its chronic phase. The combination of immunosuppressive agents, such as mycophenolate mofetil, with corticosteroids has shown potential benefits in improving disease control and reducing the need for corticosteroids.
Article Details
Keywords
Vogt-Koyanagi-Harada syndrome, mycophenolate mofetil, corticosteroids.
References
2. Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res. May 2016;52:84-111.
3. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. Oct 2000;130(4):492-513.
4. Herbort CP, Jr., Abu El Asrar AM, Takeuchi M, et al. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease. Int Ophthalmol. Jun 2019;39(6):1419-1425.
5. Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. JAMA. Sep 10 2019;322(10):936-945.
6. Waszczyk-Laczak M, Lazicka-Galecka M, Chomicz L, Mucha K, Paczek L, Szaflik JP. The first investigation on differences in the effectiveness of mycophenolate mofetil and azathioprine antimetabolites determined in Polish patients treated for non-infectious uveitis. Ann Agric Environ Med. Dec 22 2020;27(4):644-649.
7. Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D, Abu El-Asrar AM. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. Apr-Jun 2007;27(2-3):201-10.
8. Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. Dec 2012;90(8):e603-8.